Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01038778 · ClinicalTrials.gov registry record · Phase 1

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

A Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
47
Enrollment target
4
Study locations

NCT01038778 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01038778, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
47 participants
Enrollment target
4
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Aldesleukin may stimulate the white blood cells to kill kidney cancer cells. Giving entinostat together with aldesleukin may be a better treatment for metastatic kidney cancer.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v7 Metastatic Kidney Carcinoma Stage III Renal Cell Cancer AJCC v7

Interventions

  • PROCEDURE Computed Tomography
  • OTHER Laboratory Biomarker Analysis
  • DRUG Entinostat
  • RADIATION Fludeoxyglucose F-18
  • BIOLOGICAL Aldesleukin

Study Locations (4)

California

  • USC / Norris Comprehensive Cancer Center - Los Angeles

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore

New York

  • Roswell Park Cancer Institute - Buffalo

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2009-10-29
Est. Completion 2027-02-12
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01038778

The ClinicalTrials.gov registry entry for NCT01038778 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (77% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT01038778 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT01038778 about?

NCT01038778 is a clinical study titled "Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer". This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the en...

What is the current status of trial NCT01038778?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2009-10-29. Estimated completion is 2027-02-12.

What conditions does trial NCT01038778 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7.

What interventions are being tested in trial NCT01038778?

The interventions under investigation include: Computed Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Entinostat (DRUG), Fludeoxyglucose F-18 (RADIATION), Aldesleukin (BIOLOGICAL).

Who is sponsoring clinical trial NCT01038778?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01038778 being conducted?

This trial has 4 study locations across California, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer AJCC v7

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.